Researchers at the Barcelona Institute of Science and Technology’s Center for Genomic Regulation (CRG) and Pulmobiotics Ltd. have used one bacterium to fight another. In mouse models, the team used engineered Mycoplasma pneumoniae to treat Pseudomonas aeruginosa, the chief culprit in ventilator-associated pneumonia (VAP). Read More

The discovery of two new sarcoma-specific pathways and 14 new genes that predispose people to heritable sarcomas could pave the way to managing cancer risk early via detection of these mutations for this rare type of cancer. Sarcomas are rare connective tissue malignancies mostly derived from embryonic mesoderm and affect younger people. Read More

Researchers from Guangzhou Institutes of Biomedicine and Health and CSIRO presented the discovery and preclinical characterization of novel compounds with high activity against androgen receptor (AR)-dependent prostate cancer cells. Read More

Mabwell Therapeutics Inc., a wholly owned subsidiary of Mabwell (Shanghai) Bioscience Co. Ltd., has entered into a license agreement with Disc Medicine Inc. for 9MW3011 (MWTX-001, MWTX-002 & MWTX-003) for hematologic diseases. Read More

Mirati Therapeutics Inc. has received FDA clearance of its IND application for MRTX-1133, a potent, oral small-molecule inhibitor of the KRAS G12D driver mutation. Read More

Recently, it has been found that loss-of-function of TPC2 alkalized melanosomes promoted pigmentation, while gain-of-function of TPC2 acidified melanosomes and inhibited melanin synthesis. Read More

Bacterial abortive infection is a defense mechanism by which an infected bacterial cell enters dormancy or dies to limit phage replication and protect the clonal population. Recent studies observed that CRISPR RNA-guided adaptive immune systems that target RNA also cause abortive-infection phenotypes by activating indiscriminate nucleases. Read More

Kumquat Biosciences Inc. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer. Read More

Insilico Medicine Inc. has divulged β-lactam derivatives acting as glutaminyl-peptide cyclotransferase-like protein (QPCTL) inhibitors reported to be useful for the treatment of cancer, Alzheimer's diseases, atherosclerosis, chronic kidney disease, infertility, ischemia-reperfusion injury, schizophrenia and Zollinger-Ellison syndrome, among others. Read More

Polymeric nanoparticles selectively accumulate in solid tumors in part due to tumor-associated angiogenesis without efficient lymphatic drainage exerting an enhanced permeation and retention (EPR) effect. Many radiotherapies fail due to poor tumor cell selectivity. Read More

LG Chem has described urea derivatives acting as macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer and immunological disorders. Read More

Gilgamesh Pharmaceuticals Inc. has identified arylcyclo-hexylamine derivatives targeting N-methyl-D-aspartate receptor (NMDAR) and/or serotonin transporter (SERT) reported to be useful for the treatment of substance abuse and dependence, depression and mood and anxiety disorders. Read More

TANK-binding kinase 1 (TBK1) is a multifunctional serine/threonine kinase with an established role coordinating innate immune responses, and it has been previously identified as a candidate immune evasion gene. Additionally, disrupting TBK1 signaling has shown potential for enhancing response to immunotherapy with immune checkpoint blockade (ICB) in murine tumor models. Read More

Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's disease, hepatic fibrosis, viral infections, inflammatory disorders and polycystic kidney. Read More